NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

Search

Coloplast A-S (Class B)

Slēgts

727.4 0.86

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

722

Max

737.6

Galvenie mērījumi

By Trading Economics

Ienākumi

-270M

1B

Pārdošana

73M

7B

P/E

Sektora vidējais

33.45

73.239

EPS

6.38

Dividenžu ienesīgums

3.03

Peļņas marža

14.859

Darbinieki

16,628

EBITDA

-42M

2.2B

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+11.86% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.03%

3.06%

Nākamie ieņēmumi

2025. g. 6. maijs

Nākamais Ex dividenžu datums

2025. g. 12. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

164B

Iepriekšējā atvēršanas cena

726.54

Iepriekšējā slēgšanas cena

727.4

Coloplast A-S (Class B) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 31. marts 22:45 UTC

Top Ziņas

Intel's New CEO Plots Turnaround; 'We Need to Improve'

2025. g. 31. marts 23:54 UTC

Tirgus saruna

Nikkei May Rise After Monday's Selloff -- Market Talk

2025. g. 31. marts 23:44 UTC

Tirgus saruna

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

2025. g. 31. marts 23:15 UTC

Tirgus saruna

Tower Shares Ease After Bain Capital Exit -- Market Talk

2025. g. 31. marts 23:15 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 31. marts 22:33 UTC

Top Ziņas

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

2025. g. 31. marts 22:28 UTC

Peļņas

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

2025. g. 31. marts 22:28 UTC

Peļņas

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

2025. g. 31. marts 22:28 UTC

Peļņas

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

2025. g. 31. marts 22:28 UTC

Peļņas

China Vanke Swings to Loss for 2024 >000002.SZ

2025. g. 31. marts 21:47 UTC

Top Ziņas

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

2025. g. 31. marts 21:44 UTC

Top Ziņas

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

2025. g. 31. marts 21:21 UTC

Tirgus saruna

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

2025. g. 31. marts 21:18 UTC

Top Ziņas

Copper Is 2025's Hottest Commodity -- Update

2025. g. 31. marts 21:09 UTC

Top Ziņas

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

2025. g. 31. marts 21:02 UTC

Peļņas

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

2025. g. 31. marts 21:01 UTC

Peļņas

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

2025. g. 31. marts 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 31. marts 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 31. marts 20:37 UTC

Top Ziņas

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

2025. g. 31. marts 20:17 UTC

Top Ziņas

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

2025. g. 31. marts 20:13 UTC

Top Ziņas

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

2025. g. 31. marts 20:03 UTC

Top Ziņas

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

2025. g. 31. marts 19:09 UTC

Tirgus saruna

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

2025. g. 31. marts 18:56 UTC

Tirgus saruna

U.S. Natural Gas Gains With Help From Weather -- Market Talk

2025. g. 31. marts 18:54 UTC

Tirgus saruna

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

2025. g. 31. marts 18:40 UTC

Tirgus saruna

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

2025. g. 31. marts 18:34 UTC

Tirgus saruna

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

2025. g. 31. marts 18:28 UTC

Tirgus saruna

Gold Climbs to Close Out Quarter -- Market Talk

2025. g. 31. marts 18:03 UTC

Top Ziņas

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Salīdzinājums

Cenas izmaiņa

Coloplast A-S (Class B) Prognoze

Cenas mērķis

By TipRanks

11.86% augšup

Prognoze 12 mēnešiem

Vidējais 901.38 DKK  11.86%

Augstākais 1,056 DKK

Zemākais 720 DKK

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Coloplast A-S (Class B) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

8 ratings

2

Pirkt

4

Turēt

2

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.